Chronic Renal Failure Clinical Trial
Official title:
TRIFIR : Study of Trabecular Bone Score (TBS) as a Fracture Risk Factor in Chronic Renal Failure
Observational study
The Trabecular Bone Score (TBS) is a recent imaging tool that indirectly studies bone
microarchitecture from 2-dimensional images of lumbar biphotonic absorptiometry (DXA). His
interest is demonstrated in the evaluation of the fracture risk of the general population.
The study of its interest in chronic renal failure is ongoing, only 3 studies have been
published to our knowledge.
Osteopathy of chronic renal failure is a complex phenomenon involving bone remodeling
disorders, mineralization, mass and bone microarchitecture. In the renal transplant
population, certain factors, such as anti-rejection therapy, are also involved.
The impact of fragility fractures induced by these disorders of bone metabolism is a major
public health issue due to the resulting morbidity and mortality, with mortality doubling in
comparison to the general population after a hip fracture.
The bone osteopathy assessment of chronic renal failure is the bone biopsy, however its
realization is very limited because of its invasiveness.
Although initially Bone Densitometry was not recommended in the evaluation of the fracture
risk of chronic renal failure by KDIGO (Kidney Disease Improvement Global Outcomes) of 2009,
many works published since plead in favor of its realization for the fracture risk
assessment, in combination with the clinical data of the Fracture Risk Assessment Tool
(FRAX), as should be recommended in the next KDIGO. Indeed, the decrease in bone density in
chronic renal failure is associated with an increased risk of fracture.
Clinical parameters, of course, also play an important role in the evaluation of the fracture
risk of chronic renal insufficiency, be it the items taken into account in FRAX, certain
factors related to chronic kidney disease, or even transplantation. kidney transplant.
To our knowledge, only three studies on the association of TBS with fracture risk of chronic
renal failure have been published. In particular, they show a significant association between
the decrease in TBS and the incident fracture risk, independently of bone density and FRAX,
in a population of kidney transplant recipients, and chronic renal insufficiency in stage 3
or 4.
According to KDIGO 2009, the only biomarkers recommended in the evaluation of osteopathy
chronic renal failure are parathyroid hormone (PTH) and bone-specific alkaline phosphatase
(BAP), although there is no established threshold for significant increase in fracture risk .
However, there is little data on other bone remodeling markers such as the Procollagen type 1
N-terminal propeptide (P1NP) and the C-terminal telopeptide of type 1 collagen (CTX). Some
studies indicate, however, that they may be of interest in evaluation of osteopathy of
chronic renal failure .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 |